TS logo

Tenaris S.A. American Depositary Shares (TS)

$56.52

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TS

Market cap

$29.92B

EPS

3.66

P/E ratio

15.3

Price to sales

2.49

Dividend yield

4.176%

Beta

0.855584

Price on TS

Previous close

$56.30

Today's open

$56.57

Day's range

$56.24 - $57.02

52 week range

$33.65 - $64.60

Profile about TS

CEO

Gabriel Podskubka

Employees

29134

Headquarters

Luxembourg,

Exchange

New York Stock Exchange

Shares outstanding

529450331

Issue type

American Depository Receipt

TS industries and sectors

Energy

Fossil Fuels

News on TS

Tenaris: Q2 Earnings Don't Make The Upside Any Better, Maintain Hold

Tenaris is rated 'HOLD' with a price target of €16/share ($36.91 ADR), reflecting cyclical risks and recent overvaluation. TS faces near-term headwinds from Hormuz shipment delays, margin compression, and declining revenues, signaling a mid-cycle to early downcycle transition. While TS maintains a strong balance sheet and leading market position, its earnings power remains tightly linked to volatile energy CapEx cycles.

news source

Seeking Alpha • Aug 12, 2026

news preview

Tenaris Q2 Earnings Call Highlights

Tenaris NYSE: TS reported second-quarter sales of $3 billion, down 4% from both a year earlier and the prior quarter, as shipping disruptions in the Middle East delayed deliveries to customers in Iraq, Kuwait and Qatar.

news source

MarketBeat • Aug 9, 2026

news preview

Tenaris S.A. (TS) Q2 2026 Earnings Call Transcript

Tenaris S.A. (TS) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 6, 2026

news preview

Tenaris Announces 2026 Second Quarter Results

The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Free Cash Flow, Net cash / debt and Operating working capital days. See exhibit I for more details on these alternative performance measures.

news source

GlobeNewsWire • Aug 5, 2026

news preview

Compared to Estimates, Tenaris (TS) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Tenaris (TS) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

news source

Zacks Investment Research • Aug 6, 2026

news preview

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (August 2026)

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.2%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.

news source

Seeking Alpha • Aug 5, 2026

news preview

Why Tenaris S.A. (TS) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Tenaris (TS) have what it takes?

news source

Zacks Investment Research • Aug 3, 2026

news preview

Tenaris S.A. (TS) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Tenaris (TS) have what it takes?

news source

Zacks Investment Research • Jul 15, 2026

news preview

NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Toronto, Ontario – TheNewswire - July 15, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced the initiation of its Phase IIb clinical trial site at  Hannover Medical School, Hanover (“MHH”), Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults.   The trial, which previously received regulatory clearance from Germany's Federal Institute for Drugs and Medical Devices and MHH's ethics committee , is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects.

news preview

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (July 2026)

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.1%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.

news source

Seeking Alpha • Jul 11, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Tenaris S.A. American Depositary Shares

Open an M1 investment account to buy and sell Tenaris S.A. American Depositary Shares commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TS on M1